ストックスクリーナーアプリを入手
11.77
0.51%
0.06
プレマーケット:
11.77
Keros Therapeutics Inc (KROS) 最新ニュース
(KROS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts - MarketBeat
KROS stock: Does the Takeda deal lower dilution risk in 2026? - MSN
Sarcopenia Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirsc - Barchart
Insmed (INSM) soars 5.5%: Is further upside left in the stock? - MSN
Keros Therapeutics (KROS) to Release Quarterly Earnings on Tuesday - MarketBeat
Keros gains Orphan Drug designation for Duchenne muscular dystrophy asset - MSN
Responsive Playbooks and the KROS Inflection - Stock Traders Daily
KROS|Keros Therapeutics Inc|Price:11.510|Chg%:-0.05 - TradingKey
ADAR1 Capital Management urges Keros Therapeutics for board change - MSN
Why is Keros Therapeutics (KROS) up 2.5% since last earnings report? - MSN
Keros Therapeutics (KROS) Business Update | Q4 2025: Earnings UnderperformShared Buy Zones - Cổng thông tin điện tử tỉnh Lào Cai
[ARS] Keros Therapeutics, Inc. SEC Filing - Stock Titan
Keros Therapeutics (NASDAQ: KROS) focuses on rinvatercept and completes $375M capital return - Stock Titan
KROS SEC FilingsKeros Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
KROS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment - The Globe and Mail
KROS Rinvatercept: What to Know Before DMD Phase II Starts - Barchart
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026? - TradingView
Keros Therapeutics (KROS) Stock: Growth vs Risks (Momentum Fading) 2026-04-20Verified Stock Signals - Cổng thông tin điện tử tỉnh Lào Cai
Bienaime buys Keros Therapeutics (KROS) shares worth $11,700 By Investing.com - Investing.com India
Insider Buying: Jean Bienaime Acquires Additional Shares of Keros Therapeutics Inc (KROS) - GuruFocus
Bienaime buys Keros Therapeutics (KROS) shares worth $11,700 - Investing.com
Keros Therapeutics (NASDAQ:KROS) Director Acquires $11,700.00 in Stock - MarketBeat
[Form 4] Keros Therapeutics, Inc. Insider Trading Activity - Stock Titan
Keros Therapeutics, Inc. (KROS) Stock Analysis: Exploring a Potential 92.59% Upside in the Biotech Industry - DirectorsTalk Interviews
Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Down 24.9% in March - MarketBeat
Understanding the Setup: (KROS) and Scalable Risk - Stock Traders Daily
Wall Street Recap: Can Keros Therapeutics Inc weather a recessionWeekly Gains Report & Risk Managed Investment Strategies - baoquankhu1.vn
Wedbush Maintains Keros Therapeutics (KROS) Neutral Recommendation - MSN
Is Keros Therapeutics (KROS) Stock Breaking Out | Price at $11.60, Down 7.13%Portfolio Management - UBND thành phố Hải Phòng
Is Keros Therapeutics (KROS) Stock heavily shorted | Price at $12.50, Up 2.12%Viral Momentum Stocks - Xã Thanh Hà
BlackRock (KROS) reports 1.99M-share, 10.1% passive stake in Keros Therapeutics - Stock Titan
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Rating of "Hold" from Analysts - MarketBeat
Keros Therapeutics (KROS) CEO exercises options for 55,000 shares - Stock Titan
JPMorgan Chase & Co. Raises Position in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics, Inc. $KROS Shares Acquired by SG Americas Securities LLC - MarketBeat
Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report? - Yahoo Finance
The Technical Signals Behind (KROS) That Institutions Follow - Stock Traders Daily
Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last? - MSN
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):